Therapeutic Plasma Exchange Market Size, Share, Industry Trends and Forecast to 2030

Therapeutic Plasma Exchange Market Size & CAGR in 2021

The global therapeutic plasma exchange market is expected to reach a value of USD 1.2 billion in 2021, with a Compound Annual Growth Rate (CAGR) of 5.8% from 2021 to 2025. This growth is attributed to the increasing prevalence of autoimmune diseases, neurological disorders, and blood-related disorders worldwide. Therapeutic plasma exchange, also known as plasmapheresis, is a procedure in which plasma is separated from the blood and replaced with a replacement solution, such as albumin or saline.

COVID-19 Impact on the Therapeutic Plasma Exchange Market

The COVID-19 pandemic has had a significant impact on the therapeutic plasma exchange market. The global healthcare system faced challenges in providing adequate treatment to patients with autoimmune and neurological disorders due to the overwhelming number of COVID-19 cases. This led to disruptions in the supply chain of therapeutic plasma exchange equipment and consumables. However, with the gradual control of the pandemic and the increasing focus on healthcare infrastructure, the market is expected to recover and witness steady growth in the coming years.

Therapeutic Plasma Exchange Dynamics

The therapeutic plasma exchange market is driven by the rising incidences of autoimmune diseases, neurological disorders, and hematological disorders globally. The procedure is increasingly being used as a treatment option for conditions such as Guillain-Barré syndrome, myasthenia gravis, and thrombotic thrombocytopenic purpura. Advancements in plasma exchange technology, such as automated apheresis systems, have improved the efficiency and safety of the procedure, further driving market growth.

Segments and Related Analysis

The therapeutic plasma exchange market is segmented based on products, applications, end-users, and regions. By product, the market is divided into devices and consumables. Applications of therapeutic plasma exchange include autoimmune diseases, neurological disorders, hematological disorders, and others. End-users of the procedure include hospitals, clinics, and ambulatory surgical centers. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

By Region Analysis

- North America: The North American region dominates the therapeutic plasma exchange market due to the high prevalence of autoimmune diseases and neurological disorders, as well as well-established healthcare infrastructure.

- Europe: Europe is also a significant market for therapeutic plasma exchange, with a growing focus on research and development in the field of plasma exchange technology.

- Asia Pacific: The Asia Pacific region is witnessing rapid growth in the therapeutic plasma exchange market due to the increasing awareness about autoimmune diseases and the improving healthcare facilities.

- Latin America: Latin America shows promising growth opportunities in the therapeutic plasma exchange market, with a rising prevalence of hematological disorders in the region.

- Middle East & Africa: The Middle East & Africa region is expected to witness steady growth in the therapeutic plasma exchange market, supported by the growing investments in healthcare infrastructure.

Key Market Players and Competitive Landscape

The key players in the therapeutic plasma exchange market include Terumo Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Haemonetics Corporation, Asahi Kasei Corporation, B. Braun Melsungen AG, Cerus Corporation, Kawasumi Laboratories Inc., Kaneka Corporation, and Nikkiso Co., Ltd. These companies are focusing on product innovations, strategic collaborations, and mergers to strengthen their market presence and expand their product portfolios.

Recent Happenings in the Therapeutic Plasma Exchange Market

- In July 2021, Terumo Corporation launched a new therapeutic plasma exchange system with advanced features for efficient plasma separation and replacement.

- In September 2021, Fresenius SE & Co. KGaA announced the acquisition of a leading manufacturer of apheresis equipment, expanding its product offerings in the therapeutic plasma exchange market.

- In January 2022, Baxter International Inc. introduced a novel software platform for monitoring and managing therapeutic plasma exchange procedures, enhancing the safety and efficacy of the treatment.

- In March 2022, Haemonetics Corporation collaborated with a research institute to develop a next-generation therapeutic plasma exchange device with improved automation and precision.

- In May 2022, Cerus Corporation received regulatory approval for its innovative plasma exchange kit, providing healthcare providers with a convenient and reliable solution for performing the procedure.